

Breast Cancer Pathways

Patient Name: _____

Date of Birth: _____

Member ID: _____

Treatment Start Date: _____

Stage: _____

Pathology: _____

ECOG Status: 1 2 3 4 5

ICD-10 Code: _____

Line of Therapy: 1st Line 2nd Line

3rd Line 3rd Line +

Biomarkers/Attributes: (select all that apply)

Estrogen Receptor (ER) Negative Positive

Menopausal Status: Pre Post

Progesterone Receptor (PR) Negative Positive

Peri N/A (male)

HER2 FISH/CISH Negative Positive

Equivocal Include ovarian suppression

HER2 IHC 0 1+ 2+ 3+

Oncotype Dx: Low Intermediate High Not Done/Reported

Neoadjuvant/Adjuvant

HER2 Negative

- Doxorubicin + Cyclophosphamide (dose dense) → Paclitaxel weekly (ddAc → weekly T)
- Doxorubicin + Cyclophosphamide (dose dense) → Paclitaxel every 2 weeks (ddAc → q2w T)
- Docetaxel + Cyclophosphamide (TC)

HER2 Positive

- Doxorubicin + Cyclophosphamide → Paclitaxel weekly + Trastuzumab* (AC → TH)
- Docetaxel + Carboplatin + Trastuzumab* (TCH)
- Paclitaxel + Trastuzumab*

Adjuvant (Residual Disease Post-Neoadjuvant Treatment)

HER2 Negative

- Capecitabine

HER2 Positive

- Ado-trastuzumab emtansine (T-DM1)

Metastatic and Recurrent – Endocrine Therapy

HER2 Negative | First Line of Therapy

- Anastrozole
- Letrozole
- Exemestane
- Tamoxifen

Note: Pathways are independent of specific Optum Care/health plan medical policy coverage criteria. Optum Care/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by health plan formularies, medical policies, or preferred product rules.

- Fulvestrant
- Abemaciclib + anastrozole
- Abemaciclib + exemestane
- Abemaciclib + letrozole
- Palbociclib + Anastrozole
- Palbociclib + exemestane
- Palbociclib + letrozole
- Ribociclib + Anastrozole
- Ribociclib + exemestane
- Ribociclib + letrozole
- Anastrozole + fulvestrant
- Letrozole + fulvestrant
- Abemaciclib + fulvestrant
- Palbociclib + fulvestrant
- Ribociclib + fulvestrant

HER2 Negative | Second + Subsequent Lines of Therapy

- Anastrozole
- Letrozole
- Exemestane
- Tamoxifen
- Fulvestrant
- Fulvestrant + Palbociclib
- Fulvestrant + Abemaciclib
- Fulvestrant + Ribociclib
- Alpelisib + fulvestrant (PIK3CA, HR+, HER2- only)

HER2 Positive | All Lines of Therapy

- Anastrozole + Trastuzumab*
- Letrozole + Trastuzumab*
- Exemestane + Trastuzumab*
- Anastrozole + Lapatinib
- Letrozole + Lapatinib
- Exemestane + Lapatinib

Note: Pathways are independent of specific Optum Care/health plan medical policy coverage criteria. Optum Care/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by health plan formularies, medical policies, or preferred product rules.

Metastatic and Recurrent – Chemotherapy

HER2 Negative | First and Subsequent Lines of Therapy

- Doxorubicin
- Paclitaxel
- Docetaxel
- Capecitabine
- Gemcitabine
- Vinorelbine
- Atezolizumab + nab-Paclitaxel (in PDL1+ mTNBC only)
- Olaparib (BRCA 1/2 only)
- Talazoparib (BRCA 1/2 only)

HER2 Positive | First and Subsequent Lines of Therapy

- Docetaxel + Trastuzumab* + Pertuzumab
- Paclitaxel + Trastuzumab* + Pertuzumab
- Tucatinib + Trastuzumab* + capecitabine
- Ado-trastuzumab Emtansine (TDM-1)
- Paclitaxel + Trastuzumab*
- Vinorelbine + Trastuzumab*
- Capecitabine + Trastuzumab*
- Gemcitabine + Trastuzumab*

*a biosimilar agent may be preferred under the patient's specific health plan

Note: Pathways are independent of specific Optum Care/health plan medical policy coverage criteria. Optum Care/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by health plan formularies, medical policies, or preferred product rules.

References:

- A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE). ClinicalTrials.gov identifier: NCT01120184. Updated November 7, 2017. Accessed March 18, 2021. <https://www.clinicaltrials.gov/ct2/show/results/NCT01120184>.
- Albain KS, Nag SM, Calderillo-Ruiz G, et al. Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. *J Clin Oncol.* 2008;26(24):3950-3957. doi:10.1200/JCO.2007.11.9362
- Anderson GL, Chlebowski RT, Aragaki AK, et al. Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. *Lancet Oncol.* 2012;13(5):476-486. doi:10.1016/S1470-2045(12)70075-X
- André F, Ciruelos E, Rubovszky G, et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. *N Engl J Med.* 2019;380(20):1929-1940. doi:10.1056/NEJMoa1813904
- André F, Ciruelos EM, Juric D, et al. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1. *Ann Oncol.* 2021;32(2):208-217. doi:10.1016/j.annonc.2020.11.011
- Bachelot T, Bourcier C, Cropet C, et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. *J Clin Oncol.* 2012;30(22):2718-2724. doi:10.1200/JCO.2011.39.0708
- Bang SM, Heo DS, Lee KH, et al. Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma. *Cancer.* 2000;89(12):2521-2526. doi:10.1002/1097-0142(20001215)89:12<2521::aid-cnrc2>3.0.co;2-f
- Bardia A, Mayer IA, Vahdat LT, et al. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer. *N Engl J Med.* 2019;380(8):741-751. doi:10.1056/NEJMoa1814213
- Baselga J, Cortés J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. *N Engl J Med.* 2012;366(2):109-119. doi:10.1056/NEJMoa1113216.
- Bastholt L, Dalmark M, Gjedde SB, et al. Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group. *J Clin Oncol.* 1996;14(4):1146-1155. doi:10.1200/JCO.1996.14.4.1146
- Blackwell KL, Burstein HJ, Storniolo AM, et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. *J Clin Oncol.* 2012;30(21):2585-2592. doi:10.1200/JCO.2011.35.6725.
- Blackwell KL, Burstein HJ, Storniolo AM, et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. *J Clin Oncol.* 2010;28(7):1124-1130. doi:10.1200/JCO.2008.21.4437.
- Budd GT, Barlow WE, Moore HC, et al. SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. *J Clin Oncol.* 2015;33(1):58-64. doi:10.1200/JCO.2014.56.3296
- Burstein HJ, Keshaviah A, Baron AD, et al. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. *Cancer.* 2007;110(5):965-972. doi:10.1002/cncr.22885
- Buzdar A, Douma J, Davidson N, et al. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. *J Clin Oncol.* 2001;19(14):3357-3366. doi:10.1200/JCO.2001.19.14.3357
- Byrski T, Dent R, Blecharz P, et al. Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer. *Breast Cancer Res.* 2012;14(4):R110. Published 2012 Jul 20. doi:10.1186/bcr3231

Note: Pathways are independent of specific Optum Care/health plan medical policy coverage criteria. Optum Care/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by health plan formularies, medical policies, or preferred product rules.

Cameron D, Piccart-Gebhart MJ, Gelber RD, et al. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial [published correction appears in *Lancet*. 2019 Mar 16;393(10176):1100]. *Lancet*. 2017;389(10075):1195–1205. doi:10.1016/S0140-6736(16)32616-2

Chan A, Delaloge S, Holmes FA, et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol*. 2016;17(3):367–377. doi:10.1016/S1470-2045(15)00551-3

Chan S, Friedrichs K, Noel D, et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. *J Clin Oncol*. 1999;17(8):2341-2354. doi:10.1200/JCO.1999.17.8.2341

Citron ML, Berry DA, Cirincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741 [published correction appears in *J Clin Oncol*. 2003 Jun 1;21(11):2226]. *J Clin Oncol*. 2003;21(8):1431-1439. doi:10.1200/JCO.2003.09.081

Cortes J, Cescon DW, Rugo HS, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. *Lancet*. 2020;396(10265):1817-1828. doi:10.1016/S0140-6736(20)32531-9

Cortes J, O'Shaughnessy J, Loesch D, et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. *Lancet*. 2011;377(9769):914-923. doi:10.1016/S0140-6736(11)60070-6

Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial [published correction appears in *Lancet Oncol*. 2016 Apr;17 (4):e136] [published correction appears in *Lancet Oncol*. 2016 Jul;17 (7):e270]. *Lancet Oncol*. 2016;17(4):425-439. doi:10.1016/S1470-2045(15)00613-0

Dang C, Fornier M, Sugarman S, et al. The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER2/neu overexpressed/amplified breast cancer. *J Clin Oncol*. 2008;26(8):1216-1222. doi:10.1200/JCO.2007.12.0733

Dang C, Iyengar N, Datko F, et al. Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer [published correction appears in *J Clin Oncol*. 2019 Feb 1;37(4):354]. *J Clin Oncol*. 2015;33(5):442-447. doi:10.1200/JCO.2014.57.1745.

Di Leo A, Jerusalem G, Petruzella L, et al. Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial. *J Natl Cancer Inst*. 2014;106(1):djt337. doi:10.1093/jnci/djt337

Di Leo A, Jerusalem G, Petruzella L, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer [published correction appears in *J Clin Oncol*. 2011 Jun 1;29(16):2293]. *J Clin Oncol*. 2010;28(30):4594-4600. doi:10.1200/JCO.2010.28.8415

Dickler MN, Tolaney SM, Rugo HS, et al. MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer [published correction appears in *Clin Cancer Res*. 2018 Nov 1;24(21):5485]. *Clin Cancer Res*. 2017;23(17):5218-5224. doi:10.1158/1078-0432.CCR-17-0754

Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. *J Clin Oncol*. 1998;16(2):453-461. doi:10.1200/JCO.1998.16.2.453

Drilon A, Laetsch TW, Kummar S, et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. *N Engl J Med*. 2018;378(8):731-739. doi:10.1056/NEJMoa1714448

Drilon A, Siena S, Ou SI, et al. Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). *Cancer Discov*. 2017;7(4):400-409. doi:10.1158/2159-8290.CD-16-1237

Note: Pathways are independent of specific Optum Care/health plan medical policy coverage criteria. Optum Care/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by health plan formularies, medical policies, or preferred product rules.

Esteva FJ, Valero V, Booser D, et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. *J Clin Oncol.* 2002;20(7):1800-1808. doi:10.1200/JCO.2002.07.058

Feher O, Vodvarka P, Jassem J, et al. First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: a multicenter, randomized, phase III study. *Ann Oncol.* 2005;16(6):899-908. doi:10.1093/annonc/mdi181

Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. *Lancet Oncol.* 2015;16(1):25-35. doi:10.1016/S1470-2045(14)71159-3

Fisher B, Anderson S, Tan-Chiu E, et al. Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. *J Clin Oncol.* 2001;19(4):931-942. doi:10.1200/JCO.2001.19.4.931

Fisher B, Brown AM, Dimitrov NV, et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. *J Clin Oncol.* 1990;8(9):1483-1496. doi:10.1200/JCO.1990.8.9.1483

Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer [published correction appears in *N Engl J Med.* 2007 Apr 5;356(14):1487]. *N Engl J Med.* 2006;355(26):2733-2743. doi:10.1056/NEJMoa064320

Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. *Lancet.* 2010;375(9712):377-384. doi:10.1016/S0140-6736(09)61964-4

Gianni L, Pienkowski T, Im YH, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. *Lancet Oncol.* 2016;17(6):791-800. doi:10.1016/S1470-2045(16)00163-7

Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. *Lancet Oncol.* 2012;13(1):25-32. doi:10.1016/S1470-2045(11)70336-9

Goetz MP, Toi M, Campone M, et al. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. *J Clin Oncol.* 2017;35(32):3638-3646. doi:10.1200/JCO.2017.75.6155
Johnston S, Martin M, Di Leo A, et al. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. *NPJ Breast Cancer.* 2019;5:5. Published 2019 Jan 17. doi:10.1038/s41523-018-0097-z

Gradishar WJ, Krasnojon D, Cheporov S, et al. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer [published correction appears in *J Clin Oncol.* 2011 Jul 1;29(19):2739]. *J Clin Oncol.* 2009;27(22):3611-3619. doi:10.1200/JCO.2008.18.5397

Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. *J Clin Oncol.* 2005;23(31):7794-7803. doi:10.1200/JCO.2005.04.937

Gundersen S, Kvinnsland S, Klepp O, Kvaløy S, Lund E, Høst H. Weekly adriamycin versus VAC in advanced breast cancer. A randomized trial. *Eur J Cancer Clin Oncol.* 1986;22(12):1431-1434. doi:10.1016/0277-5379(86)90075-1

Harvey V, Mouridsen H, Semiglazov V, et al. Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer [published correction appears in *J Clin Oncol.* 2006 Dec 20;24(36):5790]. *J Clin Oncol.* 2006;24(31):4963-4970. doi:10.1200/JCO.2005.05.0294

Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer [published correction appears in *N Engl J Med.* 2018 Dec 27;379(26):2582]. *N Engl J Med.* 2016;375(18):1738-1748. doi:10.1056/NEJMoa1609709

Hortobagyi GN, Stemmer SM, Burris HA, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer [published correction appears in *Ann Oncol.* 2019 Nov 1;30(11):1842] [published correction appears in *Ann Oncol.* 2019 Nov;30(11):1842]. *Ann Oncol.* 2018;29(7):1541-1547. doi:10.1093/annonc/mdy155

Note: Pathways are independent of specific Optum Care/health plan medical policy coverage criteria. Optum Care/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by health plan formularies, medical policies, or preferred product rules.

Huober J, Fasching PA, Barsoum M, et al. Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial. *Breast*. 2012;21(1):27-33. doi:10.1016/j.breast.2011.07.006

Hurvitz SA, Martin M, Jung KH, et al. Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study. *J Clin Oncol*. 2019;37(25):2206–2216. doi:10.1200/JCO.19.00882

Hurvitz SA, Martin M, Symmans WF, et al. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. *Lancet Oncol*. 2018;19(1):115–126. doi:10.1016/S1470-2045(17)30716-7

Im SA, Lu YS, Bardia A, et al. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. *N Engl J Med*. 2019;381(4):307-316. doi:10.1056/NEJMoa1903765

Isakoff SJ, Mayer EL, He L, et al. TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer. *J Clin Oncol*. 2015;33(17):1902-1909. doi:10.1200/JCO.2014.57.6660

Jerusalem G, de Boer RH, Hurvitz S, et al. Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer: The BOLERO-6 Randomized Clinical Trial. *JAMA Oncol*. 2018;4(10):1367-1374. doi:10.1001/jamaoncol.2018.2262

Johnston S, Pippen J Jr, Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. *J Clin Oncol*. 2009;27(33):5538-5546. doi:10.1200/JCO.2009.23.3734

Johnston SRD, Hegg R, Im SA, et al. Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Updated Results of ALTERNATIVE. *J Clin Oncol*. 2021;39(1):79-89. doi:10.1200/JCO.20.01894

Johnston SRD, Hegg R, Im SA, et al. Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: ALTERNATIVE [retracted in: *J Clin Oncol*. 2021 Jan 1;39(1):95]. *J Clin Oncol*. 2018;36(8):741-748. doi:10.1200/JCO.2017.74.7824

Jones S, Holmes FA, O'Shaughnessy J, et al. Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735. *J Clin Oncol*. 2009;27(8):1177-1183. doi:10.1200/JCO.2008.18.4028

Jones SE, Collea R, Paul D, et al. Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study. *Lancet Oncol*. 2013;14(11):1121-1128. doi:10.1016/S1470-2045(13)70384-X

Kaufman B, Mackey JR, Clemens MR, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. *J Clin Oncol*. 2009;27(33):5529-5537. doi:10.1200/JCO.2008.20.6847

Kornblum N, Zhao F, Manola J, et al. Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102. *J Clin Oncol*. 2018;36(16):1556-1563. doi:10.1200/JCO.2017.76.9331

Lala M, Li TR, de Alwis DP, et al. A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation [published correction appears in *Eur J Cancer*. 2021 Feb;144:400]. *Eur J Cancer*. 2020;131:68-75. doi:10.1016/j.ejca.2020.02.016.

Langley RE, Carmichael J, Jones AL, et al. Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute trial AB01. *J Clin Oncol*. 2005;23(33):8322-8330. doi:10.1200/JCO.2005.01.1817

Note: Pathways are independent of specific Optum Care/health plan medical policy coverage criteria. Optum Care/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by health plan formularies, medical policies, or preferred product rules.

Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. *Science*. 2017;357(6349):409-413. doi:10.1126/science.aan6733. Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. *N Engl J Med*. 2015;372(26):2509-2520. doi:10.1056/NEJMoa1500596.

Licchetta A, Correale P, Migali C, et al. Oral metronomic chemo-hormonal-therapy of metastatic breast cancer with cyclophosphamide and megestrol acetate. *J Chemother*. 2010;22(3):201-204. doi:10.1179/joc.2010.22.3.201

Liombart-Cussac A, Ruiz A, Antón A, et al. Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer: final results from the Spanish Breast Cancer Group 2001-03 phase 2 randomized trial. *Cancer*. 2012;118(1):241-247. doi:10.1002/cncr.26299

Litton JK, Rugo HS, Ettl J, et al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. *N Engl J Med*. 2018;379(8):753-763. doi:10.1056/NEJMoa1802905

Loesch D, Robert N, Asmar L, et al. Phase II multicenter trial of a weekly paclitaxel and carboplatin regimen in patients with advanced breast cancer. *J Clin Oncol*. 2002;20(18):3857-3864. doi:10.1200/JCO.2002.08.129

Loibl S, O'Shaughnessy J, Untch M, et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. *Lancet Oncol*. 2018;19(4):497-509. doi:10.1016/S1473-2045(18)30111-6

Mackey JR, Martin M, Pienkowski T, et al. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. *Lancet Oncol*. 2013;14(1):72-80. doi:10.1016/S1473-2045(12)70525-9

Mamounas EP, Bryant J, Lembersky B, et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. *J Clin Oncol*. 2005;23(16):3686-3696. doi:10.1200/JCO.2005.10.517

Martin M, Holmes FA, Ejlertsen B, et al. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol*. 2017;18(12):1688-1700. doi:10.1016/S1473-2045(17)30717-9

Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. *N Engl J Med*. 2005;352(22):2302-2313. doi:10.1056/NEJMoa043681

Masuda N, Lee SJ, Ohtani S, et al. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. *N Engl J Med*. 2017;376(22):2147-2159. doi:10.1056/NEJMoa1612645

Mehta RS, Barlow WE, Albain KS, et al. Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer [published correction appears in *N Engl J Med*. 2019 Jun 06;380(23):2282]. *N Engl J Med*. 2019;380(13):1226-1234. doi:10.1056/NEJMoa1811714

Milla-Santos A, Milla L, Rallo L, Solano V. Phase III randomized trial of toremifene vs tamoxifen in hormonodependant advanced breast cancer. *Breast Cancer Res Treat*. 2001;65(2):119-124. doi:10.1023/a:1006440802709

Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. *N Engl J Med*. 2007;357(26):2666-2676. doi:10.1056/NEJMoa072113

Mirtsching B, Cosgriff T, Harker G, Keaton M, Chidiac T, Min M. A phase II study of weekly nanoparticle albumin-bound paclitaxel with or without trastuzumab in metastatic breast cancer. *Clin Breast Cancer*. 2011;11(2):121-128. doi:10.1016/j.clbc.2011.03.007

Modi S, Saura C, Yamashita T, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. *N Engl J Med*. 2020;382(7):610-621. doi:10.1056/NEJMoa1914510

Mouridsen H, Gershanovich M, Sun Y, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. *J Clin Oncol*. 2003;21(11):2101-2109. doi:10.1200/JCO.2003.04.194

Note: Pathways are independent of specific Optum Care/health plan medical policy coverage criteria. Optum Care/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by health plan formularies, medical policies, or preferred product rules.

Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group [published correction appears in *J Clin Oncol*. 2001 Jul 1;19(13):3302]. *J Clin Oncol*. 2001;19(10):2596-2606. doi:10.1200/JCO.2001.19.10.2596

Murthy RK, Loi S, Okines A, et al. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer [published correction appears in *N Engl J Med*. 2020 Feb 6;382(6):586]. *N Engl J Med*. 2020;382(7):597-609. doi:10.1056/NEJMoa1914609

Nabholtz JM, Falkson C, Campos D, et al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial [published correction appears in *J Clin Oncol*. 2003 May 15;21(10):2048]. *J Clin Oncol*. 2003;21(6):968-975. doi:10.1200/JCO.2003.04.040

O'Brien ME, Wigler N, Inbar M, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. *Ann Oncol*. 2004;15(3):440-449. doi:10.1093/annonc/mdh097.

O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. *J Clin Oncol*. 2002;20(12):2812-2823. doi:10.1200/JCO.2002.09.002

O'Shaughnessy J, Schwartzberg L, Danso MA, et al. Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. *J Clin Oncol*. 2014;32(34):3840-3847. doi:10.1200/JCO.2014.55.2984

O'Shaughnessy JA, Vukelja S, Marsland T, Kimmel G, Ratnam S, Pippen JE. Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer. *Clin Breast Cancer*. 2004;5(2):142-147. doi:10.3816/cbc.2004.n.019

Paridaens RJ, Dirix LY, Beex LV, et al. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. *J Clin Oncol*. 2008;26(30):4883-4890. doi:10.1200/JCO.2007.14.4659

Perez EA, Barrios C, Eiermann W, et al. Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study [published correction appears in *J Clin Oncol*. 2017 Jul 10;35(20):2342] [published correction appears in *J Clin Oncol*. 2019 Feb 1;37(4):358]. *J Clin Oncol*. 2017;35(2):141-148. doi:10.1200/JCO.2016.67.4887

Perez EA, Hillman DW, Stella PJ, et al. A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinoma. *Cancer*. 2000;88(1):124-131. doi:10.1002/(sici)1097-0142(20000101)88:1<124::aid-cnrcr17>3.3.co;2-6

Perez EA, Lerzo G, Pivot X, et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. *J Clin Oncol*. 2007;25(23):3407-3414. doi:10.1200/JCO.2006.09.3849

Perez EA, Romond EH, Suman VJ, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. *J Clin Oncol*. 2014;32(33):3744-3752. doi:10.1200/JCO.2014.55.5730

Perez EA, Vogel CL, Irwin DH, Kirshner JJ, Patel R. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. *J Clin Oncol*. 2001;19(22):4216-4223. doi:10.1200/JCO.2001.19.22.4216

Piccart M, Hortobagyi GN, Campone M, et al. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†. *Ann Oncol*. 2014;25(12):2357-2362. doi:10.1093/annonc/mdu456.

Piccart MJ, Di Leo A, Beauduin M, et al. Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. *J Clin Oncol*. 2001;19(12):3103-3110. doi:10.1200/JCO.2001.19.12.3103

Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. *N Engl J Med*. 2005;353(16):1659-1672. doi:10.1056/NEJMoa052306

Note: Pathways are independent of specific Optum Care/health plan medical policy coverage criteria. Optum Care/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by health plan formularies, medical policies, or preferred product rules.

Rivera E, Mejia JA, Arun BK, et al. Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer. *Cancer*. 2008;112(7):1455-1461. doi:10.1002/cncr.23321

Robson M, Im SA, Senkus E, et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation [published correction appears in *N Engl J Med*. 2017 Oct 26;377(17):1700]. *N Engl J Med*. 2017;377(6):523-533. doi:10.1056/NEJMoa1706450

Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. *N Engl J Med*. 2005;353(16):1673-1684. doi:10.1056/NEJMoa052122

Rugo HS, Im SA, Cardoso F, et al. Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial [published online ahead of print, 2021 Jan 22]. *JAMA Oncol*. 2021;e207932. doi:10.1001/jamaoncol.2020.7932

Sakaguchi K, Nakatsukasa K, Koyama H, et al. Phase II Clinical Trial of First-line Eribulin Plus Trastuzumab for Advanced or Recurrent HER2-positive Breast Cancer. *Anticancer Res*. 2018;38(7):4073-4081. doi:10.21873/anticancer.12697

Saura C, Oliveira M, Feng YH, et al. Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial. *J Clin Oncol*. 2020;38(27):3138-3149. doi:10.1200/JCO.20.00147

Saura C, Oliveira M, Feng YH, et al. Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial. *J Clin Oncol*. 2020;38(27):3138-3149. doi:10.1200/JCO.20.00147Bartsch R, Wenzel C, Altorjai G, et al. Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. *J Clin Oncol*. 2007;25(25):3853-3858. doi:10.1200/JCO.2007.11.9776

Schmid P, Adams S, Rugo HS, et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. *N Engl J Med*. 2018;379(22):2108-2121. doi:10.1056/NEJMoa1809615

Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for Early Triple-Negative Breast Cancer. *N Engl J Med*. 2020;382(9):810-821. doi:10.1056/NEJMoa1910549

Schneeweiss A, Chia S, Hickish T, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). *Ann Oncol*. 2013;24(9):2278-2284. doi:10.1093/annonc/mdt182

Sharma P, López-Tarruella S, García-Saenz JA, et al. Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts. *Clin Cancer Res*. 2017;23(3):649-657. doi:10.1158/1078-0432.CCR-16-0162

Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. *N Engl J Med*. 2011;365(14):1273-1283. doi:10.1056/NEJMoa0910383

Slamon DJ, Neven P, Chia S, et al. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. *N Engl J Med*. 2020;382(6):514-524. doi:10.1056/NEJMoa1911149Slamon DJ, Neven P, Chia S, et al. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. *N Engl J Med*. 2020;382(6):514-524. doi:10.1056/NEJMoa1911149

Slamon DJ, Neven P, Chia S, et al. Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. *J Clin Oncol*. 2018;36(24):2465-2472. doi:10.1200/JCO.2018.78.9909

Sledge GW Jr, Toi M, Neven P, et al. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. *J Clin Oncol*. 2017;35(25):2875-2884. doi:10.1200/JCO.2017.73.7585

Sledge GW Jr, Toi M, Neven P, et al. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial [published online ahead of print, 2019 Sep 29]. *JAMA Oncol*. 2019;6(1):116-124. doi:10.1001/jamaoncol.2019.4782

Smyth LM, Iyengar NM, Chen MF, et al. Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study. *Breast Cancer Res Treat*. 2016;158(1):91-97. doi:10.1007/s10549-016-3851-7

Note: Pathways are independent of specific Optum Care/health plan medical policy coverage criteria. Optum Care/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by health plan formularies, medical policies, or preferred product rules.

Sparano JA, Wang M, Martino S, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer [published correction appears in N Engl J Med. 2008 Jul 3;359(1):106] [published correction appears in N Engl J Med. 2009 Apr 16;360(16):1685]. N Engl J Med. 2008;358(16):1663-1671. doi:10.1056/NEJMoa0707056 and Supplemental Appendix.

Sparano JA, Zhao F, Martino S, et al. Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer. J Clin Oncol. 2015;33(21):2353-2360. doi:10.1200/JCO.2015.60.9271

Stockler MR, Harvey VJ, Francis PA, et al. Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer. J Clin Oncol. 2011;29(34):4498-4504. doi:10.1200/JCO.2010.33.9101

Swain SM, Baselga J, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372(8):724-734. doi:10.1056/NEJMoa1413513

Swain SM, Ewer MS, Viale G, et al. Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study. Ann Oncol. 2018;29(3):646-653. doi:10.1093/annonc/mdx773

Tolaney SM, Barry WT, Dang CT, et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer [published correction appears in N Engl J Med. 2015 Nov 12;373(20):1989]. N Engl J Med. 2015;372(2):134-141. doi:10.1056/NEJMoa1406281

Tripathy D, Im S-A, Colleoni M, et al. Updated overall survival (OS) results from the phase III MONALEESA-7 trial of pre- or perimenopausal patients with HR+/HER2- advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib. Presented at the San Antonio Breast Cancer Symposium, December 9, 2020. Abstract #PD2-04.

Tripathy D, Im SA, Colleoni M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018;19(7):904-915. doi:10.1016/S1470-2045(18)30292-4

Turner NC, Slamon DJ, Ro J, et al. Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. N Engl J Med. 2018;379(20):1926-1936. doi:10.1056/NEJMoa1810527

Tutt A, Tovey H, Cheang MCU, et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nat Med. 2018;24(5):628-637. doi:10.1038/s41591-018-0009-7

Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer [published correction appears in N Engl J Med. 2013 Jun 20;368(25):2442]. N Engl J Med. 2012;367(19):1783-1791. doi:10.1056/NEJMoa1209124

von Minckwitz G, du Bois A, Schmidt M, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. J Clin Oncol. 2009;27(12):1999-2006. doi:10.1200/JCO.2008.19.6618

von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med. 2019;380(7):617-628. doi:10.1056/NEJMoa1814017

von Minckwitz G, Procter M, de Azambuja E, et al. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer [published correction appears in N Engl J Med. 2017 Aug 17;377(7):702] [published correction appears in N Engl J Med. 2018 Oct 18;379(16):1585]. N Engl J Med. 2017;377(2):122-131. doi:10.1056/NEJMoa1703643

von Minckwitz G, Raab G, Caputo A, et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARUO study of the German Breast Group. J Clin Oncol. 2005;23(12):2676-2685. doi:10.1200/JCO.2005.05.07

Wang R, Smyth LM, Iyengar N, et al. Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5-Year Follow-up. Oncologist. 2019;24(8):e646-e652. doi:10.1634/theoncologist.2018-0512

Note: Pathways are independent of specific Optum Care/health plan medical policy coverage criteria. Optum Care/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by health plan formularies, medical policies, or preferred product rules.

Yardley DA, Burris HA 3rd, Hanson S, et al. Weekly gemcitabine and trastuzumab in the treatment of patients with HER2-overexpressing metastatic breast cancer. *Clin Breast Cancer*. 2009;9(3):178-183. doi:10.3816/CBC.2009.n.029

Yardley DA, Burris HA 3rd, Spigel DR, Clark BL, Vazquez E, Shipley D, Barton J, Thompson D, Montes I, Greco FA, Hainsworth JD. A phase II randomized crossover study of liposomal doxorubicin versus weekly docetaxel in the first-line treatment of women with metastatic breast cancer. *Clin Breast Cancer*. 2009 Nov;9(4):247-52. doi: 10.3816/CBC.2009.n.042. PMID: 19933081.

Yardley DA, Coleman R, Conte P, et al. nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial. *Ann Oncol*. 2018;29(8):1763-1770. doi:10.1093/annonc/mdy201

Yardley DA, Noguchi S, Pritchard KI, et al. Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis [published correction appears in *Adv Ther*. 2014 Sep;31(9):1008-9]. *Adv Ther*. 2013;30(10):870-884. doi:10.1007/s12325-013-0060-1.

Zelev L, Barthier S, Riofrio M, et al. Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma. *Cancer*. 2001;92(9):2267-2272. doi:10.1002/1097-0142(20011101)92:9<2267::aid-cnrc1572>3.0.co;2-q

Note: Pathways are independent of specific Optum Care/health plan medical policy coverage criteria. Optum Care/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by health plan formularies, medical policies, or preferred product rules.